KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Long-Term Deferred Tax (2016 - 2025)

Historic Long-Term Deferred Tax for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Q3 2025 value amounting to $1.5 billion.

  • Biomarin Pharmaceutical's Long-Term Deferred Tax fell 141.56% to $1.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 billion, marking a year-over-year decrease of 141.56%. This contributed to the annual value of $1.5 billion for FY2024, which is 365.14% down from last year.
  • Per Biomarin Pharmaceutical's latest filing, its Long-Term Deferred Tax stood at $1.5 billion for Q3 2025, which was down 141.56% from $1.4 billion recorded in Q2 2025.
  • In the past 5 years, Biomarin Pharmaceutical's Long-Term Deferred Tax registered a high of $1.5 billion during Q1 2024, and its lowest value of $1.4 billion during Q2 2025.
  • Moreover, its 5-year median value for Long-Term Deferred Tax was $1.5 billion (2024), whereas its average is $1.5 billion.
  • In the last 5 years, Biomarin Pharmaceutical's Long-Term Deferred Tax soared by 16470.6% in 2021 and then plummeted by 763.65% in 2025.
  • Quarter analysis of 5 years shows Biomarin Pharmaceutical's Long-Term Deferred Tax stood at $1.5 billion in 2021, then rose by 3.81% to $1.5 billion in 2022, then increased by 2.68% to $1.5 billion in 2023, then dropped by 3.65% to $1.5 billion in 2024, then grew by 1.33% to $1.5 billion in 2025.
  • Its last three reported values are $1.5 billion in Q3 2025, $1.4 billion for Q2 2025, and $1.5 billion during Q1 2025.